Monday, 20 Nov 2017

You are here

Chondroitin Effective in Knee OA. Or is it?

Reginster and colleagues have reported on the results of the CONCEPT trial showing that osteoarthritis (OA) patients treated 800 mg/day of  pharmaceutical-grade chondroitin sulfate (CS) have less VAS pain scores and improved function over 6 months therapy. These results were superior to placebo and equivalent to celecoxib in reducing in symptomatic OA knee pain.

They enrolled 603 OA knee patients a 6-month, 3-arm, double-blind, double-dummy trial were patients were randomized to either placebo, CS and celecoxib (200 mg/day). After 6 mos, greater improvement in Pain VAS scores were seen with CS (-42.6 mm) and celecoxib (−39.5 mm) versus those treated with placebo (−33.3 mm) (p=0.001 for CS and p=0.009 for celecoxib vs PBO).

Figure 2 

So is chondroitin as effective as NSAID therapy?  The problem is that many prior studies of CS use in knee OA have yielded mixed results. ( Citation source: http://buff.ly/2rqc0hE)

These data are limited by fair low effect size, the trial being sponsored by the CS manufacturer and prior claims showing selective benefit of a specific manufacturer compared to other manufacturers.

While the results are encouraging, further study by other parties is advisable.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee

Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.

Zilretta is the commonly used triamcinolon acetonide combined with a drug delivery system designed to provide extended pain relief over three months.

UAB Researchers Shed Light on Age-Related Osteoporosis

Researchers from the University of Alabama at Birmingham (UAB) have detailed mechanisms leading to age-related bone loss and osteoporosis.

Osteoporotic Fractures as Back Pain in Older Men

The Journal of Bone and Mineral Research reports that older men with undiagnosed vertebral fractures are likely to report new or worsening back pain. (Citation source bit.ly/2y9rMiZ)

Romosuzumab Followed by Alendronate is Best in Fracture Prevention

The NEJM reports that in high risk post-menopausal women, romosozumab for 12 months followed by alendronate resulted in a significantly lower fracture than alendronate alone. 

Bad Knees Through the Ages

The average American today is twice as likely to be diagnosed with knee osteoarthritis as in the years before World War II, Harvard scientists say. And the reasons are less clear than you might think.

Based on a study of more than 2,000 skeletons from cadaveric and archaeological collections across the United States, a Harvard report is the first to definitively show that knee osteoarthritis prevalence has dramatically increased in recent decades.